325 related articles for article (PubMed ID: 30508156)
1. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients.
Shitara K; Yamanaka T; Denda T; Tsuji Y; Shinozaki K; Komatsu Y; Kobayashi Y; Furuse J; Okuda H; Asayama M; Akiyoshi K; Kagawa Y; Kato T; Oki E; Ando T; Hagiwara Y; Ohashi Y; Yoshino T
Ann Oncol; 2019 Feb; 30(2):259-265. PubMed ID: 30508156
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
[TBL] [Abstract][Full Text] [Related]
3. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
[TBL] [Abstract][Full Text] [Related]
4. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.
Élez E; Kocáková I; Höhler T; Martens UM; Bokemeyer C; Van Cutsem E; Melichar B; Smakal M; Csőszi T; Topuzov E; Orlova R; Tjulandin S; Rivera F; Straub J; Bruns R; Quaratino S; Tabernero J
Ann Oncol; 2015 Jan; 26(1):132-140. PubMed ID: 25319061
[TBL] [Abstract][Full Text] [Related]
5. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
6. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
[TBL] [Abstract][Full Text] [Related]
8. Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
Moretto R; Rossini D; Capone I; Boccaccino A; Perrone F; Tamborini E; Masi G; Antoniotti C; Marmorino F; Conca V; Borelli B; Martignetti A; Pecora I; Simionato F; Cupini S; Ambrosini M; Manca P; Pietrantonio F; Falcone A; Cremolini C
Clin Colorectal Cancer; 2021 Dec; 20(4):314-317. PubMed ID: 34364814
[TBL] [Abstract][Full Text] [Related]
9. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
Brodowicz T; Ciuleanu TE; Radosavljevic D; Shacham-Shmueli E; Vrbanec D; Plate S; Mrsic-Krmpotic Z; Dank M; Purkalne G; Messinger D; Zielinski CC
Ann Oncol; 2013 Jul; 24(7):1769-1777. PubMed ID: 23559149
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frödin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Mauro DJ; Watkins DJ
J Natl Cancer Inst; 2015 Dec; 107(12):djv258. PubMed ID: 26405092
[TBL] [Abstract][Full Text] [Related]
11. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
12. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
13. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Tai CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Chao Y; Teng HW
Am J Clin Oncol; 2020 Jan; 43(1):28-34. PubMed ID: 31693507
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
[TBL] [Abstract][Full Text] [Related]
15. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
Bridgewater JA; Pugh SA; Maishman T; Eminton Z; Mellor J; Whitehead A; Stanton L; Radford M; Corkhill A; Griffiths GO; Falk S; Valle JW; O'Reilly D; Siriwardena AK; Hornbuckle J; Rees M; Iveson TJ; Hickish T; Garden OJ; Cunningham D; Maughan TS; Primrose JN;
Lancet Oncol; 2020 Mar; 21(3):398-411. PubMed ID: 32014119
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Ciardiello F; Normanno N; Martinelli E; Troiani T; Pisconti S; Cardone C; Nappi A; Bordonaro AR; Rachiglio M; Lambiase M; Latiano TP; Modoni G; Cordio S; Giuliani F; Biglietto M; Montesarchio V; Barone C; Tonini G; Cinieri S; Febbraro A; Rizzi D; De Vita F; Orditura M; Colucci G; Maiello E;
Ann Oncol; 2016 Jun; 27(6):1055-1061. PubMed ID: 27002107
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.
Masuishi T; Tsuji A; Kotaka M; Nakamura M; Kochi M; Takagane A; Shimada K; Denda T; Segawa Y; Tanioka H; Hara H; Sagawa T; Watanabe T; Takahashi T; Negoro Y; Manaka D; Fujita H; Suto T; Takeuchi M; Ichikawa W; Fujii M
Br J Cancer; 2020 Nov; 123(10):1490-1495. PubMed ID: 32863385
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
